Merck and Moderna announced that their personalized neoantigen mRNA vaccine, intismeran autogene, met a pivotal Phase 3 endpoint in high-risk melanoma, a result regulators and investors are now likely to scrutinize for approval readiness. The regimen pairs the individualized mRNA vaccine with Merck’s Keytruda (pembrolizumab) in the adjuvant setting after surgical tumor removal. Company statements indicated the therapy significantly improved recurrence-free survival at interim analysis and demonstrated a secondary improvement in distant metastasis-free survival, with no new safety signals highlighted. The partners framed the readout as a first randomized Phase 3 trial aimed at proving benefit for neoantigen vaccines. Market reaction has been swift, with coverage suggesting investors are comparing the potential impact to Keytruda’s role in melanoma. Further details—including final endpoint reporting and durability—will determine whether this study translates into regulatory acceptance beyond interim success.